285 related articles for article (PubMed ID: 36102147)
21. Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.
Sada KE; Yamamura M; Harigai M; Fujii T; Takasaki Y; Amano K; Fujimoto S; Muso E; Murakawa Y; Arimura Y; Makino H;
Arthritis Res Ther; 2015 Nov; 17():305. PubMed ID: 26525413
[TBL] [Abstract][Full Text] [Related]
22. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies.
Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Fujimoto S; Dobashi H; Yuzawa Y; Yamagata K; Muso E; Arimura Y; Makino H
Mod Rheumatol; 2021 Jan; 31(1):205-213. PubMed ID: 31859544
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering.
Ono N; Kai T; Takeyama Y; Inoue Y; Ueda N; Nagano S; Ohta S; Inoue H; Sawabe T; Chifu Y; Yoshizawa S; Oryoji K; Kimoto Y; Miyake K; Ayano M; Mitoma H; Arinobu Y; Miyamura T; Horiuchi T; Akashi K; Tada Y; Niiro H
Int J Rheum Dis; 2024 Jan; 27(1):e15009. PubMed ID: 38129977
[TBL] [Abstract][Full Text] [Related]
24. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
25. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Turkiewicz A; Tchao NK; Webber L; Ding L; Sejismundo LP; Mieras K; Weitzenkamp D; Ikle D; Seyfert-Margolis V; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh KA; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Specks U;
N Engl J Med; 2010 Jul; 363(3):221-32. PubMed ID: 20647199
[TBL] [Abstract][Full Text] [Related]
26. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
28. Remission and Low Disease Activity in Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual.
Delvino P; Sardanelli F; Monti S; Cohen P; Puéchal X; Mouthon L; Montecucco C; Guillevin L; Terrier B
Arthritis Care Res (Hoboken); 2023 May; 75(5):1158-1165. PubMed ID: 35604889
[TBL] [Abstract][Full Text] [Related]
29. Biologics for ANCA-associated vasculitis.
Murgia G; Firinu D; Manconi PE; Del Giacco SR
Inflamm Allergy Drug Targets; 2014; 13(4):275-87. PubMed ID: 24998311
[TBL] [Abstract][Full Text] [Related]
30. ANCA-Associated Vasculitis: Core Curriculum 2020.
Geetha D; Jefferson JA
Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
32. Corticosteroids in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Keller SF; Miloslavsky EM
Rheum Dis Clin North Am; 2016 Feb; 42(1):91-101, viii. PubMed ID: 26611553
[TBL] [Abstract][Full Text] [Related]
33. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
34. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice.
Chevet B; Cornec D; Casal Moura M; Cornec-Le Gall E; Fervenza FC; Warrington KJ; Specks U; Berti A
Rheumatology (Oxford); 2023 May; 62(5):1787-1803. PubMed ID: 36315063
[TBL] [Abstract][Full Text] [Related]
35. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.
Plumb LA; Oni L; Marks SD; Tullus K
Pediatr Nephrol; 2018 Jan; 33(1):25-39. PubMed ID: 28062909
[TBL] [Abstract][Full Text] [Related]
36. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.
Lally L; Spiera R
Rheum Dis Clin North Am; 2015; 41(1):1-19, vii. PubMed ID: 25399936
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
38. Remission maintenance in ANCA-associated vasculitis: does one size fit all?
Berti A; Specks U
Expert Rev Clin Immunol; 2019 Dec; 15(12):1273-1286. PubMed ID: 31762340
[No Abstract] [Full Text] [Related]
39. Targeted immunotherapy strategies in ANCA-associated vasculitis.
Puéchal X
Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
[TBL] [Abstract][Full Text] [Related]
40. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
